Table 1.

Main clinical and laboratory data at baseline of individual patientsa

PatientAge (yr)GenderDisease Duration (mo)Renal BiopsybPrevious TherapiescLaboratory Characteristics at Baseline
Serum Creatinine (mg/dl)Urinary Protein Excretion (g/24 h)Serum Albumin (g/dl)Serum Cholesterol (mg/dl)
119M24NOSST 1 mg/kg per d (6)1.216.01.8520
GGS 10%TAC 0.08 mg/kg per d (9)
0MMF 1.5 g/d (3)
229M36TipST 1 mg/kg per d (6)0.916.51.4690
GGS 9%Cycl 1.5 mg/kg per d (3)
+CsA 5 mg/kg per d (6)
MMF 1 g/d (6)
334M36NOSST 0.4 mg/kg per d (24)1.49.42.2262
GGS 0%CsA 3.5 mg/kg per d (18)
0TAC 0.05 mg/kg per d (8)
MMF 1 g/d (6)
419M25NOSST 1 mg/kg per d (6)0.912.01.8550
GGS 0%CsA 5 mg/kg per d (6)
0MMF 2 g/d (6)
555M24NOSST 1 mg/kg per d (6)0.99.81.7430
GGS 16%CSA 5 mg/kg per d (12)
+
651M107CELLST 0.7 mg/kg per d (8)2.312.71.8
GGS 15%CsA 2.5 mg/kg per d (16)
+MMF 1 g/d (12)
720M30NOSST 0.4 mg/kg per d (12)1.712.92.0221
GGS 0%CsA 3.5 mg/kg per d (1)
+TAC 0.05 mg/kg per d (30)
MMF 1 g/d (27)
823F95NOSST 0.3 mg/kg per d (30)1.923.01.3263
GGS 30%Cycl 1 mg/kg per d (3)
++CsA 4 mg/kg per d (12)
MMF 2 g/d (24)
  • a CsA, cyclosporine; Cycl, cyclophosphamide; MMF, mycophenolate mofetil; ST, steroids; TAC, tacrolimus.

  • b The pathologic variant of FSGS is expressed (NOS, not otherwise specified; Tip, tip lesion; CELL, cellular variant), as well as the percentage of glomeruli showing global sclerosis (GGS) and the severity of interstitial fibrosis (0, absent; +, mild; ++, moderate; +++, severe).

  • c Mean dosages and duration in months (in parentheses) expressed after every drug.